Developer docs
API playgroundTry for free, no card

Search company profiles

Amphera

Full company profile

uuid002l3y7

Namestring
Amphera
Legal namestring
Amphera B.V.
Websiteurl
amphera.nl
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Amphera B.V. is a privately held, late-clinical-stage biotechnology company headquartered in 's-Hertogenbosch, Netherlands, founded in December 2012 as a spin-off from Erasmus Medical Center in Rotterdam. The company's lead product is MesoPher, an Advanced Therapy Medicinal Product (ATMP) that combines autologous monocyte-derived dendritic cells with PheraLys, Amphera's proprietary allogeneic lysate produced from clinically characterized mesothelioma cell lines. The lysate provides a broad, standardized repertoire of tumour-associated antigens, allowing the ex vivo-loaded dendritic cells to bypass the immunosuppressive tumour microenvironment, migrate to lymph nodes, and induce systemic NK-, B-, and T-cell responses that can convert immunologically 'cold' tumours into 'hot' tumours. MesoPher has demonstrated an excellent safety profile across multiple trials and meaningful immunological and clinical activity in both malignant mesothelioma (pleural and peritoneal) and pancreatic ductal adenocarcinoma.

Amphera's clinical pipeline spans Phase II and Phase II/III studies, including the Horizon 2020-funded DENIM trial across six European mesothelioma referral centers (results published in The Lancet Oncology, June 2024), the REACTIVE Phase II in resected pancreatic cancer (published in the Journal of Clinical Oncology, July 2024, showing 64% two-year recurrence-free survival versus an expected ~40%), the MESOPEC Phase II in peritoneal mesothelioma following HIPEC-CRS, the ENSURE trial, and the REACTIVE-2 investigator-sponsored study combining MesoPher with Alligator Bioscience's CD40 agonist mitazalimab in metastatic pancreatic cancer (published in Nature Communications, December 2025). The company holds FDA and EMA Orphan Drug Designations for both mesothelioma (granted 2014) and pancreatic cancer (EMA positive opinion June 2023; FDA September 2024), providing up to 10 years of post-approval market exclusivity in the EU on each indication.

Amphera has no commercialized products and generates no product revenue. Its business model is structured around regulatory approval via the EMA and FDA, with MesoPher designed as a personalized cell therapy administered at specialist academic centers such as Erasmus MC; upon approval, the company expects to monetize through direct hospital administration and/or licensing or partnership deals with larger pharmaceutical companies for global commercialization. Manufacturing currently relies on a GMP-compliant ATMP process produced per patient. Key partners include Erasmus MC as founding academic and principal investigator site, the Dutch Pancreatic Cancer Group for the upcoming randomized Phase II/III program, Alligator Bioscience for combination therapy development, and a six-center European consortium for the DENIM trial. Funding has come from regional Dutch investors (Brabant Life Sciences Seed Fund, Lupus Ventures, Reggeborgh Medical, De Mandemakers Groep), a RedMedTech Ventures loan of €350,000, and Horizon 2020 EU grant funding for DENIM.

Short descriptiontext

Amphera B.V. is a Dutch late-clinical-stage biotechnology company developing MesoPher, an autologous dendritic cell immunotherapy loaded with the proprietary allogeneic tumour lysate PheraLys, targeting malignant mesothelioma and pancreatic cancer under FDA and EMA Orphan Drug Designations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Headquarters's-hertogenbosch, Netherlands
HQ citystring
's-hertogenbosch
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dendritic cell therapy, cancer immunotherapy, cell therapy platform, ATMP manufacturing, tumor lysate products
Industry2 codes
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Oncology Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Cell Therapy Product (MesoPher)
TypeOne Time License
Description

Amphera is a late-stage clinical biotech with no commercialized products yet. Revenue will depend on regulatory approval and commercialization of MesoPher cell therapy for mesothelioma and pancreatic cancer. MesoPher is produced as a personalized ATMP for individual patients.

amphera.nl
2Licensing / Partnering Deals
TypeLicensing Royalties
Description

Amphera intends to attract financing and partners to fund late-stage clinical trials and bring MesoPher to market. Licensing deals with larger pharmaceutical companies represent a potential revenue pathway, as indicated by CEO statements referencing the need for partners and funding for Phase II/III trials.

amphera.nl
3Orphan Drug Market Exclusivity (Post-Approval)
TypeLicensing Royalties
Description

EMA orphan designation provides 10 years of market exclusivity for approved products. Combined with FDA orphan designation, this provides regulatory-protected market exclusivity in both the US and EU for mesothelioma and pancreatic cancer indications.

amphera.nl
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MesoPher
Description

Amphera's lead product - a cell therapy comprised of autologous dendritic cells loaded with PheraLys, an allogeneic lysate of mesothelioma cell lines. Used for treatment of mesothelioma and pancreatic cancer.

amphera.nl
+1 more record
Core offering1 text field

Amphera develops MesoPher, a personalized Advanced Therapy Medicinal Product (ATMP) cell therapy for the treatment of mesothelioma and pancreatic cancer. MesoPher is manufactured per patient by isolating monocytes from the patient's blood, differentiating them ex vivo into dendritic cells, and loading those dendritic cells with PheraLys, Amphera's proprietary allogeneic tumour cell lysate derived from characterized clinical-grade mesothelioma cell lines. The activated dendritic cells are then re-administered to the patient to induce systemic NK-cell, B-cell, and T-cell immune responses against tumour-associated antigens.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 64% 2-year recurrence-free survival in resected pancreatic cancer (REACTIVE Phase II, n=38) vs expected 40%
+7 more records
Product overview1 text field

Amphera is a late-stage biotechnology company developing MesoPher, a personalized cell therapy platform comprised of two key products: MesoPher (autologous dendritic cells loaded with proprietary PheraLys allogeneic tumor cell lysate) and PheraLys (the antigen component). MesoPher is manufactured from the patient's own blood cells via leukapheresis, isolating monocytes that are differentiated ex-vivo into dendritic cells, loaded with PheraLys, and returned to the patient to induce immune responses against tumors. The company is advancing clinical programs in pleural mesothelioma, peritoneal mesothelioma, and pancreatic cancer, with multiple Phase II/III trials completed or ongoing.

Product and service1 record
1MesoPher
CategoryCell Therapy / Oncology Biologics
Description

MesoPher is Amphera's lead product candidate, a personalized Advanced Therapy Medicinal Product (ATMP) cell therapy comprised of autologous dendritic cells loaded ex vivo with PheraLys, the company's proprietary allogeneic tumour cell lysate derived from clinical-grade mesothelioma cell lines. It is administered to patients with malignant mesothelioma (pleural and peritoneal) and pancreatic cancer to induce systemic NK-cell, B-cell, and T-cell immune responses against the tumour.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-26
Description

Alligator Bioscience and Amphera are co-developing mitazalimab (Alligator's CD40 agonist) in combination with MesoPher (Amphera's dendritic cell therapy) in the REACTIVE-2 Phase 1 trial for metastatic pancreatic cancer. The combination leverages the mechanistic synergy between MesoPher (which loads dendritic cells with TAAs) and mitazalimab (which activates those DCs via CD40), based on compelling preclinical data published in Journal for ImmunoTherapy of Cancer. REACTIVE-2 is an investigator-sponsored trial at Erasmus Medical Center. Results were published in Nature Communications in December 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Erasmus MC is Amphera's founding academic partner — Amphera is a spin-off from Erasmus MC where MesoPher was originally developed by Prof. Joachim Aerts and colleagues. Erasmus MC is the principal investigator site for all Amphera-sponsored and investigator-sponsored clinical trials including REACTIVE, REACTIVE-2, DENIM, ENSURE, and MESOPEC. Prof. Aerts serves as medical advisor and Prof. Casper van Eijck serves as principal investigator for pancreatic cancer trials.

3Dutch Pancreatic Cancer Group (DPCG)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

DPCG, described as one of the world's leading research groups in pancreatic cancer, has committed to participate in the upcoming randomized Phase II/III trial in resected pancreatic cancer. This partnership validates the scientific credibility of Amphera's approach and provides access to a broader network of pancreatic cancer research centers across the Netherlands.

amphera.nl
4Six European Mesothelioma Referral Centers (DENIM Consortium)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Six mesothelioma referral centers across five European countries participated in the DENIM Phase II/III trial, including CHRU Lille (France, hosted a DENIM consortium meeting in 2018). The consortium included academic medical centers with expertise in mesothelioma treatment and research.

amphera.nl
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sotio is developing autologous dendritic cell-based vaccines (e.g., DCVAC products for prostate cancer). A direct peer in the autologous DC immunotherapy space with similar target indications and product format as MesoPher.

TypeEmerging player
Description

DCPrime develops off-the-shelf dendritic cell vaccines (e.g., DCP-001) for hematologic malignancies and solid tumors. An emerging player in the DC-based cancer immunotherapy space using a different (allogeneic) loading approach than MesoPher.

TypeEmerging player
Description

Lytix Biopharma develops antimicrobial and oncolytic peptide-based immunotherapies that stimulate innate immunity and may pair with DC-based therapies. An emerging IO peer whose mechanism shares MesoPher's immunological "cold-to-hot" tumor conversion rationale.

TypeDirect peer
Description

AIVITA Biomedical develops patient-specific dendritic cell immunotherapies (including AV-GBM-1 and ovarian cancer candidate ROOT-001) using a similar autologous DC platform approach to MesoPher. Direct peer in autologous DC-based solid tumor therapy.

TypeBroad incumbent
Description

Adaptimmune develops engineered TCR-T cell therapies for solid tumors (e.g., Tecelra in synovial sarcoma). Comparable as a cell therapy company targeting solid tumors with a personalized autologous product, though using a different cell engineering approach than Amphera's DC platform.

TypeBroad incumbent
Description

Allogene is a leading allogeneic CAR-T developer working on off-the-shelf cell therapies for hematologic and solid tumors. A broader cell therapy peer that contrasts Amphera's autologous approach with an off-the-shelf commercial strategy.

TypeDirect peer
Description

Northwest Biotherapeutics develops DCVax, an autologous dendritic cell therapy for glioblastoma. It is the most direct competitor to Amphera in personalized DC-based cancer immunotherapy, sharing the same core technology class (ex vivo loaded autologous DCs) and similar oncology indications and regulatory milestones.

TypeEmerging player
Description

Replimune develops oncolytic virus immunotherapies designed to convert immunologically "cold" tumors into "hot" tumors — the same mechanistic rationale as MesoPher. An emerging IO peer pursuing combination strategies in solid tumor indications including mesothelioma-adjacent indications.

TypeBroad incumbent
Description

BioNTech is a major cancer immunotherapy company using mRNA and cell therapy approaches (including neoantigen vaccines and CAR-T) across solid tumor indications. A broader incumbent that overlaps with Amphera's combination strategy in pancreatic cancer IO.

TypeBroad incumbent
Description

Iovance develops autologous tumor-infiltrating lymphocyte (TIL) therapies (e.g., lifileucel), a different but related personalized cell therapy modality for solid tumors. Comparable as a commercial-stage autologous cell therapy player addressing similar refractory solid tumor indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amphera

Cell Therapy / Oncology Biologicsamphera.nl

Amphera B.V. is a Dutch late-clinical-stage biotechnology company developing MesoPher, an autologous dendritic cell immunotherapy loaded with the proprietary allogeneic tumour lysate PheraLys, targeting malignant mesothelioma and pancreatic cancer under FDA and EMA Orphan Drug Designations.

What Amphera does

Amphera B.V. is a privately held, late-clinical-stage biotechnology company headquartered in 's-Hertogenbosch, Netherlands, founded in December 2012 as a spin-off from Erasmus Medical Center in Rotterdam. The company's lead product is MesoPher, an Advanced Therapy Medicinal Product (ATMP) that combines autologous monocyte-derived dendritic cells with PheraLys, Amphera's proprietary allogeneic lysate produced from clinically characterized mesothelioma cell lines. The lysate provides a broad, standardized repertoire of tumour-associated antigens, allowing the ex vivo-loaded dendritic cells to bypass the immunosuppressive tumour microenvironment, migrate to lymph nodes, and induce systemic NK-, B-, and T-cell responses that can convert immunologically 'cold' tumours into 'hot' tumours. MesoPher has demonstrated an excellent safety profile across multiple trials and meaningful immunological and clinical activity in both malignant mesothelioma (pleural and peritoneal) and pancreatic ductal adenocarcinoma.

Amphera's clinical pipeline spans Phase II and Phase II/III studies, including the Horizon 2020-funded DENIM trial across six European mesothelioma referral centers (results published in The Lancet Oncology, June 2024), the REACTIVE Phase II in resected pancreatic cancer (published in the Journal of Clinical Oncology, July 2024, showing 64% two-year recurrence-free survival versus an expected ~40%), the MESOPEC Phase II in peritoneal mesothelioma following HIPEC-CRS, the ENSURE trial, and the REACTIVE-2 investigator-sponsored study combining MesoPher with Alligator Bioscience's CD40 agonist mitazalimab in metastatic pancreatic cancer (published in Nature Communications, December 2025). The company holds FDA and EMA Orphan Drug Designations for both mesothelioma (granted 2014) and pancreatic cancer (EMA positive opinion June 2023; FDA September 2024), providing up to 10 years of post-approval market exclusivity in the EU on each indication.

Amphera has no commercialized products and generates no product revenue. Its business model is structured around regulatory approval via the EMA and FDA, with MesoPher designed as a personalized cell therapy administered at specialist academic centers such as Erasmus MC; upon approval, the company expects to monetize through direct hospital administration and/or licensing or partnership deals with larger pharmaceutical companies for global commercialization. Manufacturing currently relies on a GMP-compliant ATMP process produced per patient. Key partners include Erasmus MC as founding academic and principal investigator site, the Dutch Pancreatic Cancer Group for the upcoming randomized Phase II/III program, Alligator Bioscience for combination therapy development, and a six-center European consortium for the DENIM trial. Funding has come from regional Dutch investors (Brabant Life Sciences Seed Fund, Lupus Ventures, Reggeborgh Medical, De Mandemakers Groep), a RedMedTech Ventures loan of €350,000, and Horizon 2020 EU grant funding for DENIM.

Amphera firmographics

Firmographics
Name
Amphera
Legal name
Amphera B.V.
Website
https://amphera.nl
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Amphera B.V. is a Dutch late-clinical-stage biotechnology company developing MesoPher, an autologous dendritic cell immunotherapy loaded with the proprietary allogeneic tumour lysate PheraLys, targeting malignant mesothelioma and pancreatic cancer under FDA and EMA Orphan Drug Designations.
Ownership category
akta.pro rank

Amphera industry classification

Industry
Product category
Cell Therapy / Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Dendritic cell therapy
  • Cancer immunotherapy
  • Cell therapy platform
  • ATMP manufacturing
  • Tumor lysate products

Where Amphera is headquartered

Location

Headquarters

HQ city
's-hertogenbosch
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Amphera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Cell Therapy Product (MesoPher): Amphera is a late-stage clinical biotech with no commercialized products yet. Revenue will depend on regulatory approval and commercialization of MesoPher cell therapy for mesothelioma and pancreatic cancer. MesoPher is produced as a personalized ATMP for individual patients.
  2. Licensing / Partnering Deals: Amphera intends to attract financing and partners to fund late-stage clinical trials and bring MesoPher to market. Licensing deals with larger pharmaceutical companies represent a potential revenue pathway, as indicated by CEO statements referencing the need for partners and funding for Phase II/III trials.
  3. Orphan Drug Market Exclusivity (Post-Approval): EMA orphan designation provides 10 years of market exclusivity for approved products. Combined with FDA orphan designation, this provides regulatory-protected market exclusivity in both the US and EU for mesothelioma and pancreatic cancer indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Amphera product offering

Product offering

Core offering

Amphera develops MesoPher, a personalized Advanced Therapy Medicinal Product (ATMP) cell therapy for the treatment of mesothelioma and pancreatic cancer. MesoPher is manufactured per patient by isolating monocytes from the patient's blood, differentiating them ex vivo into dendritic cells, and loading those dendritic cells with PheraLys, Amphera's proprietary allogeneic tumour cell lysate derived from characterized clinical-grade mesothelioma cell lines. The activated dendritic cells are then re-administered to the patient to induce systemic NK-cell, B-cell, and T-cell immune responses against tumour-associated antigens.

Product overview

Amphera is a late-stage biotechnology company developing MesoPher, a personalized cell therapy platform comprised of two key products: MesoPher (autologous dendritic cells loaded with proprietary PheraLys allogeneic tumor cell lysate) and PheraLys (the antigen component). MesoPher is manufactured from the patient's own blood cells via leukapheresis, isolating monocytes that are differentiated ex-vivo into dendritic cells, loaded with PheraLys, and returned to the patient to induce immune responses against tumors. The company is advancing clinical programs in pleural mesothelioma, peritoneal mesothelioma, and pancreatic cancer, with multiple Phase II/III trials completed or ongoing.

Differentiator

Problem solved

Functional benefit

Brands

  • MesoPher: Amphera's lead product - a cell therapy comprised of autologous dendritic cells loaded with PheraLys, an allogeneic lysate of mesothelioma cell lines. Used for treatment of mesothelioma and pancreatic cancer.
  • PheraLys

Products and services

  • MesoPher MesoPher is Amphera's lead product candidate, a personalized Advanced Therapy Medicinal Product (ATMP) cell therapy comprised of autologous dendritic cells loaded ex vivo with PheraLys, the company's proprietary allogeneic tumour cell lysate derived from clinical-grade mesothelioma cell lines. It is administered to patients with malignant mesothelioma (pleural and peritoneal) and pancreatic cancer to induce systemic NK-cell, B-cell, and T-cell immune responses against the tumour.

Quantifiable outcome

  • 64% 2-year recurrence-free survival in resected pancreatic cancer (REACTIVE Phase II, n=38) vs expected 40%
  • +7 more outcomes

Companies that use Amphera

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Amphera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Amphera partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Alligator BiosciencecoreStrategic or Co-development Partner · 26 April 2023Alligator Bioscience and Amphera are co-developing mitazalimab (Alligator's CD40 agonist) in combination with MesoPher (Amphera's dendritic cell therapy) in the REACTIVE-2 Phase 1 trial for metastatic pancreatic cancer. The combination leverages the mechanistic synergy between MesoPher (which loads dendritic cells with TAAs) and mitazalimab (which activates those DCs via CD40), based on compelling preclinical data published in Journal for ImmunoTherapy of Cancer. REACTIVE-2 is an investigator-sponsored trial at Erasmus Medical Center. Results were published in Nature Communications in December 2025.
  • Erasmus MC (Rotterdam)coreStrategic or Co-development PartnerErasmus MC is Amphera's founding academic partner — Amphera is a spin-off from Erasmus MC where MesoPher was originally developed by Prof. Joachim Aerts and colleagues. Erasmus MC is the principal investigator site for all Amphera-sponsored and investigator-sponsored clinical trials including REACTIVE, REACTIVE-2, DENIM, ENSURE, and MESOPEC. Prof. Aerts serves as medical advisor and Prof. Casper van Eijck serves as principal investigator for pancreatic cancer trials.
  • Dutch Pancreatic Cancer Group (DPCG)coreStrategic or Co-development PartnerDPCG, described as one of the world's leading research groups in pancreatic cancer, has committed to participate in the upcoming randomized Phase II/III trial in resected pancreatic cancer. This partnership validates the scientific credibility of Amphera's approach and provides access to a broader network of pancreatic cancer research centers across the Netherlands.
  • Six European Mesothelioma Referral Centers (DENIM Consortium)coreStrategic or Co-development PartnerSix mesothelioma referral centers across five European countries participated in the DENIM Phase II/III trial, including CHRU Lille (France, hosted a DENIM consortium meeting in 2018). The consortium included academic medical centers with expertise in mesothelioma treatment and research.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Amphera competitors and assessment

Company assessment

Direct peers

  • Sotio: Sotio is developing autologous dendritic cell-based vaccines (e.g., DCVAC products for prostate cancer). A direct peer in the autologous DC immunotherapy space with similar target indications and product format as MesoPher.
  • AIVITA Biomedical: AIVITA Biomedical develops patient-specific dendritic cell immunotherapies (including AV-GBM-1 and ovarian cancer candidate ROOT-001) using a similar autologous DC platform approach to MesoPher. Direct peer in autologous DC-based solid tumor therapy.
  • Northwest Biotherapeutics: Northwest Biotherapeutics develops DCVax, an autologous dendritic cell therapy for glioblastoma. It is the most direct competitor to Amphera in personalized DC-based cancer immunotherapy, sharing the same core technology class (ex vivo loaded autologous DCs) and similar oncology indications and regulatory milestones.

Emerging players

  • DCPrime: DCPrime develops off-the-shelf dendritic cell vaccines (e.g., DCP-001) for hematologic malignancies and solid tumors. An emerging player in the DC-based cancer immunotherapy space using a different (allogeneic) loading approach than MesoPher.
  • Lytix Biopharma: Lytix Biopharma develops antimicrobial and oncolytic peptide-based immunotherapies that stimulate innate immunity and may pair with DC-based therapies. An emerging IO peer whose mechanism shares MesoPher's immunological "cold-to-hot" tumor conversion rationale.
  • Replimune Group: Replimune develops oncolytic virus immunotherapies designed to convert immunologically "cold" tumors into "hot" tumors — the same mechanistic rationale as MesoPher. An emerging IO peer pursuing combination strategies in solid tumor indications including mesothelioma-adjacent indications.

Broad incumbents

  • Adaptimmune: Adaptimmune develops engineered TCR-T cell therapies for solid tumors (e.g., Tecelra in synovial sarcoma). Comparable as a cell therapy company targeting solid tumors with a personalized autologous product, though using a different cell engineering approach than Amphera's DC platform.
  • Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer working on off-the-shelf cell therapies for hematologic and solid tumors. A broader cell therapy peer that contrasts Amphera's autologous approach with an off-the-shelf commercial strategy.
  • BioNTech: BioNTech is a major cancer immunotherapy company using mRNA and cell therapy approaches (including neoantigen vaccines and CAR-T) across solid tumor indications. A broader incumbent that overlaps with Amphera's combination strategy in pancreatic cancer IO.
  • Iovance Biotherapeutics: Iovance develops autologous tumor-infiltrating lymphocyte (TIL) therapies (e.g., lifileucel), a different but related personalized cell therapy modality for solid tumors. Comparable as a commercial-stage autologous cell therapy player addressing similar refractory solid tumor indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Amphera social profiles

Digital presence

Amphera compliance and trust

Trust signal

Compliance4 records

Amphera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amphera leadership team

Management profile

Number of profiles

Profiles5 records

Amphera funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amphera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amphera

What does Amphera do?

Amphera develops MesoPher, a personalized Advanced Therapy Medicinal Product (ATMP) cell therapy for the treatment of mesothelioma and pancreatic cancer. MesoPher is manufactured per patient by isolating monocytes from the patient's blood, differentiating them ex vivo into dendritic cells, and loading those dendritic cells with PheraLys, Amphera's proprietary allogeneic tumour cell lysate derived from characterized clinical-grade mesothelioma cell lines. The activated dendritic cells are then re-administered to the patient to induce systemic NK-cell, B-cell, and T-cell immune responses against tumour-associated antigens.

Is Amphera a public or private company?

Amphera is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amphera founded?

Amphera was founded in 2012. It employs 1 to 10 people.

Where is Amphera based?

Amphera is headquartered in 's-hertogenbosch, Netherlands, in the Europe region.

How does Amphera make money?

Three revenue lines are on record. Cell Therapy Product (MesoPher) is the primary driver. The others are licensing / Partnering Deals and orphan Drug Market Exclusivity (Post-Approval).

Who are Amphera's main competitors?

Direct peers on record are Sotio, AIVITA Biomedical and Northwest Biotherapeutics. Emerging players are DCPrime, Lytix Biopharma and Replimune Group. Broad incumbents are Adaptimmune, Allogene Therapeutics, BioNTech and Iovance Biotherapeutics.

Does Amphera have an API?

No public API is recorded for Amphera.

What industry is Amphera in?

Amphera's product category is Cell Therapy / Oncology Biologics. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceREACtiVe-2 Phase 1 Data Featuring Mitazalimab Demonstrate Immune Activation in Metastatic Pancreatic Cancer - To be Presented at ESMO 2025Alligator Bioscience announced upcoming presentation of Phase 1 REACtiVe-2 trial data at ESMO Congress 2025, demonstrating that its CD40 agonist mitazalimab in combination with Amphera's dendritic cell vaccine MesoPher was safe, well-tolerated, and produced enhanced systemic and local immune responses in metastatic pancreatic cancer patients. The investigator-sponsored trial at Erasmus MC Cancer Institute showed that half of patients achieved stable disease after three administrations, with post-treatment biopsies revealing increased tumor-infiltrating T cells and reduced collagen deposition. The company stated it is actively pursuing out-licensing opportunities for mitazalimab, which is ready for Phase 3 development.dlvr.itAmphera and Alligator Bioscience reveal mitazalimab-MesoPher updateAlligator Bioscience and Amphera announced the last patient in their REACTIVE-2 phase 1 trial has been dosed, evaluating mitazalimab with MesoPher in metastatic pancreatic cancer. The Rotterdam-based trial is open-label, and initial results are expected later this year. The combination aims to drive anti-tumour immunity in hard-to-treat patients.GlobeNewswireAmphera Recruits First Patients to Pivotal Phase II/III study of MesoPher to Treat Pleural MesotheliomaAmphera B.V. announced recruitment of the first patients to its pivotal phase II/III study of MesoPher for pleural mesothelioma. The DENIM study enrolls 230 adults across six European centers, with overall survival as the primary endpoint. Amphera plans to submit an EMA marketing authorization application based on the study.